172 related articles for article (PubMed ID: 35228908)
1. Efficacy of brain natriuretic peptide
Mei Z; Luo S; Chen P; Zhang Q; Zhou L; Zhu C; Zhu H; Jin L
PeerJ; 2022; 10():e12975. PubMed ID: 35228908
[TBL] [Abstract][Full Text] [Related]
2. Effect of Nicorandil Administration on Preventing Contrast-Induced Nephropathy: A Meta-Analysis.
Zhan B; Huang X; Jiang L; Bao H; Cheng X
Angiology; 2018 Aug; 69(7):568-573. PubMed ID: 28950711
[TBL] [Abstract][Full Text] [Related]
3. Preventive effect of nicorandil on contrast-induced nephropathy: a meta-analysis of randomised controlled trials.
Li S; Wang L; Liu Y; Hu Q
Intern Med J; 2018 Aug; 48(8):957-963. PubMed ID: 29740934
[TBL] [Abstract][Full Text] [Related]
4. Recombinant Brain Natriuretic Peptide for the Prevention of Contrast-Induced Nephropathy in Patients with Chronic Kidney Disease Undergoing Nonemergent Percutaneous Coronary Intervention or Coronary Angiography: A Randomized Controlled Trial.
Liu J; Xie Y; He F; Gao Z; Hao Y; Zu X; Chang L; Li Y
Biomed Res Int; 2016; 2016():5985327. PubMed ID: 26949703
[TBL] [Abstract][Full Text] [Related]
5. Brain natriuretic peptide for prevention of contrast-inducednephropathy: a meta-analysis of randomized controlled trials.
Wei XB; Jiang L; Liu XR; Yu DQ; Tan N; Chen JY; Zhou YL; He PC; Liu YH
Eur J Clin Pharmacol; 2016 Nov; 72(11):1311-1318. PubMed ID: 27695914
[TBL] [Abstract][Full Text] [Related]
6. Nicorandil Reduces the Incidence of Contrast-Induced Nephropathy in Patients Undergoing Coronary Angiography/Intervention - Systematic Review and Meta-Analysis of Randomized Controlled Trials Including GRADE Qualification.
Pranata R; Vania R; Alkatiri AA; Firman D; Lukito AA
Cardiovasc Revasc Med; 2020 Sep; 21(9):1121-1127. PubMed ID: 31959562
[TBL] [Abstract][Full Text] [Related]
7. Oral Nicorandil effectively attenuates the incidence of contrast-induced nephropathy in patients undergoing cardiac catheterization: a randomized, controlled, open-label clinical trial.
Abdollahi Moghaddam A; Baradaran Rahimi V; Morovatdar N; Rezaee R; Babalhekam SA
Int Urol Nephrol; 2023 Sep; 55(9):2327-2334. PubMed ID: 36881267
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of nicorandil treatment for prevention of contrast-induced nephropathy in high-risk patients undergoing cardiac catheterization: A prospective randomized controlled trial.
Iranirad L; Hejazi SF; Sadeghi MS; Jang SA
Cardiol J; 2017; 24(5):502-507. PubMed ID: 28281738
[TBL] [Abstract][Full Text] [Related]
9. Brain natriuretic peptide for prevention of contrast-induced nephropathy after percutaneous coronary intervention or coronary angiography.
Liu JM; Xie YN; Gao ZH; Zu XG; Li YJ; Hao YM; Chang L
Can J Cardiol; 2014 Dec; 30(12):1607-12. PubMed ID: 25418218
[TBL] [Abstract][Full Text] [Related]
10. Preventive effect of pretreatment with intravenous nicorandil on contrast-induced nephropathy in patients with renal dysfunction undergoing coronary angiography (PRINCIPLE Study).
Ko YG; Lee BK; Kang WC; Moon JY; Cho YH; Choi SH; Hong MK; Jang Y; Kim JY; Min PK; Kwon HM;
Yonsei Med J; 2013 Jul; 54(4):957-64. PubMed ID: 23709432
[TBL] [Abstract][Full Text] [Related]
11. Preventive effect of oral nicorandil on contrast-induced nephropathy in patients with renal insufficiency undergoing elective cardiac catheterization.
Fan Y; Wei Q; Cai J; Shi Y; Zhang Y; Yao L; Wang X; Lin S; Li Y; Lv J; Zhou B; Du R
Heart Vessels; 2016 Nov; 31(11):1776-1782. PubMed ID: 26874946
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of nicorandil and ranolazine in prevention of contrast-induced nephropathy in patients with mild-to-moderate renal dysfunction: a randomized controlled trial.
Yusuf J; Prakash G; Safal S; Mehta V; Mukhopadhyay S
Coron Artery Dis; 2024 May; 35(3):186-192. PubMed ID: 38411168
[TBL] [Abstract][Full Text] [Related]
13. Evaluating biomarkers for contrast-induced nephropathy following coronary interventions: an umbrella review on meta-analyses.
Mahapatro A; Nobakht S; Mukesh S; Daryagasht AA; Korsapati AR; Jain SM; Soltani Moghadam S; Moosavi R; Javid M; Hassanipour S; Prabhu SV; Keivanlou MH; Amini-Salehi E; Nayak SS
Eur J Med Res; 2024 Apr; 29(1):210. PubMed ID: 38561791
[TBL] [Abstract][Full Text] [Related]
14. Comparison of double-dose vs. usual dose of nicorandil for the prevention of contrast-induced nephropathy after cardiac catheterization.
Zeng Z; Fu X; Zhang X; Fu N
Int Urol Nephrol; 2019 Nov; 51(11):1999-2004. PubMed ID: 31385178
[TBL] [Abstract][Full Text] [Related]
15. Comparative efficacy of pharmacological interventions for contrast-induced nephropathy prevention after coronary angiography: a network meta-analysis from randomized trials.
Ma WQ; Zhao Y; Wang Y; Han XQ; Zhu Y; Liu NF
Int Urol Nephrol; 2018 Jun; 50(6):1085-1095. PubMed ID: 29404930
[TBL] [Abstract][Full Text] [Related]
16. Preventive Effects of Nicorandil Against Contrast-Induced Nephropathy in Patients With Moderate Renal Insufficiency Undergoing Percutaneous Coronary Intervention.
Zhang P; Li WY; Yang SC; Fu NK; Liu XG; Zhang X; Cong HL; Lin WH; Tian FS; Lu CZ; Zhang J
Angiology; 2020 Feb; 71(2):183-188. PubMed ID: 30987432
[TBL] [Abstract][Full Text] [Related]
17. Nicorandil for the prevention of contrast-induced nephropathy: A meta-analysis of randomized controlled trials.
Ma X; Li X; Jiao Z; Zhang Y
Cardiovasc Ther; 2018 Apr; 36(2):. PubMed ID: 29283501
[TBL] [Abstract][Full Text] [Related]
18. Continuous intravenous infusion of nicorandil for 4 hours before and 24 hours after percutaneous coronary intervention protects against contrast-induced nephropathy in patients with poor renal function.
Nawa T; Nishigaki K; Kinomura Y; Tanaka T; Yamada Y; Kawasaki M; Minatoguchi S
Int J Cardiol; 2015 Sep; 195():228-34. PubMed ID: 26048382
[TBL] [Abstract][Full Text] [Related]
19. Brain natriuretic peptide as a biomarker for predicting contrast-induced nephropathy in patients undergoing coronary angiography/intervention: A systematic review and meta-analysis.
Wu X; Yang X; Xu Z; Li J
Medicine (Baltimore); 2022 Dec; 101(52):e32432. PubMed ID: 36595981
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of short-term moderate or high-dose rosuvastatin in preventing contrast-induced nephropathy: A meta-analysis of 15 randomized controlled trials.
Liang M; Yang S; Fu N
Medicine (Baltimore); 2017 Jul; 96(27):e7384. PubMed ID: 28682890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
